表1_评估ctDNA引导的头颈鳞状细胞癌辅助治疗降级：一项比较队列研究

数据集获取（Figshare）

• 源站标题：Table 1_Evaluation of ctDNA-guided adjuvant therapy de-escalation in head and neck squamous cell carcinoma: a comparative cohort study.doc
• DOI：10.3389/fimmu.2025.1576042.s001
• 发布日期：2025-08-07
• 文件数：1 个
• 文件总体积：25.60 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table_1_Evaluation_of_ctDNA-guided_adjuvant_therapy_de-escalation_in_head_and_neck_squamous_cell_carcinoma_a_comparative_cohort_study_doc/29849885

命令行下载

curl -L -o "Table 1_Evaluation of ctDNA-guided adjuvant therapy de-escalation in head and neck squamous cell carcinoma: a comparative cohort study.doc" "https://ndownloader.figshare.com/files/57000044"

文件清单

• Table 1_Evaluation of ctDNA-guided adjuvant therapy de-escalation in head and neck squamous cell carcinoma: a comparative cohort study.doc（25.60 KB）

文件总体积 25.60 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

BackgroundWhile circulating tumor DNA (ctDNA) assessment after surgery has emerged as a promising biomarker for minimal residual disease detection in solid tumors, its clinical utility for guiding the selection between postoperative radiotherapy (PORT) and chemoradiotherapy (POCRT) in head and neck squamous cell carcinoma (HNSCC) remains poorly characterized. We evaluated whether ctDNA-directed stratification could optimize locoregional control in HNSCC patients following neoadjuvant chemoimmunotherapy.
MethodsIn this comparative cohort study, consecutive HNSCC patients treated with neoadjuvant chemoimmunotherapy were stratified into two management groups: a ctDNA-guided cohort where tumor-informed ctDNA testing determined POCRT administration given only for detectable ctDNA, and a traditional cohort where all patients received PORT, with postoperative chemotherapy decisions made by multidisciplinary team review based on pathologic response status and pretreatment imaging findings. The primary endpoint was 3-year locoregional control, with secondary analysis of POCRT utilization rates.
ResultsAmong 257 patients who completed neoadjuvant chemoimmunotherapy, 209 (81.3%) underwent surgery with 187 (72.8% of treated patients) achieving major pathological response and comprising our study population. Of these, 69 (36.9%) received ctDNA-guided management, while 118 (63.1%) followed traditional protocols. POCRT utilization was significantly lower in the ctDNA-guided group (27.5% [19/69] vs 42.4% [50/118]; absolute difference -14.9%, p=0.042). ctDNA positivity rates were comparable between groups (ctDNA-guided: 27.5% [19/69] vs traditional: 29.6% [35/118], p=0.867). ctDNA-guided management demonstrated superior outcomes, with a 15% reduction in locoregional recurrence risk (adjusted HR 0.85, 95%CI 0.70-0.94; p=0.013) versus traditional management. Among ctDNA-positive patients, POCRT benefit was significantly greater in the ctDNA-guided cohort (HR 0.73, 95%CI 0.57-0.83; p=0.026) compared to ctDNA-positive patients receiving traditional management (HR 0.87, 95%CI 0.73-0.93; p=0.047; interaction p=0.039).
ConclusionPostoperative ctDNA analysis identifies HNSCC patients wh

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fimmu.2025.1576042.s001（source: https://frontiersin.figshare.com/articles/dataset/Table_1_Evaluation_of_ctDNA-guided_adjuvant_therapy_de-escalation_in_head_and_neck_squamous_cell_carcinoma_a_comparative_cohort_study_doc/29849885）。